High-Intensity Focused Ultrasound (HIFU) for Prostate Cancer



High-intensity focused ultrasound (HIFU) is a nonsurgical treatment that uses a nonionizing physical agent. The focused ultrasound applied to tissue produces three effects (mechanical, thermal and cavitation) all of which induce irreversible tissue damage. Based on these biological effects, there is no maximum dose for HIFU, nor is there any diffusion to other organs outside of the targeted volume, and it can also be used with external beam radiotherapy (EBRT) (before or after HIFU), and it can be repeated. The HIFU treatment is performed under real-time monitoring with ultrasound (US). Two indications are validated today: primary care treatment and EBRT failure.

The results of HIFU for primary care treatment are similar to standard conformal EBRT, even though no randomized comparative studies have been performed and that no follow-up >10 years is available yet for HIFU.

Salvage HIFU after EBRT failure is increasing and one with oncological outcomes similar to those achieved with surgery but with the advantage of fewer injurious effects.

HIFU is an evolving technology perfectly adapted for focal treatment. With it, we are able to monitor temperature with MRI or US, track in real time the tissue modification with elastography and ultimately control the ablated area with MRI or contrasted US. All those technologies will be available on future HIFU devices.


Prostate Cancer Radical Prostatectomy Focal Therapy HIFU Treatment HIFU Ablation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ahmed HU, Zacharakis E, Dudderidge T, Armitage JN, Scott R, Calleary J et al (2009) High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br J Cancer 101(1):19–26PubMedCrossRefGoogle Scholar
  2. Ahmed HU, Freeman A, Kirkham A, Sahu M, Scott R, Allen C et al (2011) Focal therapy for localized prostate cancer: a phase I/II trial. J Urol 185(4): 1246–1254PubMedCrossRefGoogle Scholar
  3. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL (2011) Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 29(10):1335–1341PubMedCrossRefGoogle Scholar
  4. AURO (2009) The association of Italian urologists: guidelines, prostate cancerGoogle Scholar
  5. Beerlage HP, van Leenders GJ, Oosterhof GO, Witjes JA, Ruijter ET, van de Kaa CA et al (1999) High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. Prostate 39(1):41–46PubMedCrossRefGoogle Scholar
  6. Ben Cheikh A, Girouin N, Ryon-Taponnier P, Mege-Lechevallier F, Gelet A, Chapelon JY et al (2008) MR detection of local prostate cancer recurrence after transrectal high-intensity focused US treatment: preliminary results. J Radiol 89(5 Pt 1):571–577PubMedCrossRefGoogle Scholar
  7. Berge V, Baco E, Karlsen SJ (2010) A prospective study of salvage high-intensity focused ultrasound for locally radiorecurrent prostate cancer: early results. Scand J Urol Nephrol 44(4):223–227PubMedCrossRefGoogle Scholar
  8. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C et al (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364(18):1708–1717PubMedCrossRefGoogle Scholar
  9. Blana A, Rogenhofer S, Ganzer R, Wild PJ, Wieland WF, Walter B (2006) Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J Urol 24(5):585–590PubMedCrossRefGoogle Scholar
  10. Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C et al (2008a) First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 53(6):1194–1201PubMedCrossRefGoogle Scholar
  11. Blana A, Rogenhofer S, Ganzer R, Lunz JC, Schostak M, Wieland WF et al (2008b) Eight years’ experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology 72(6):1329–1333; discussion 33–4PubMedCrossRefGoogle Scholar
  12. Blana A, Brown SCW, Chaussy C, Conti GN, Eastham JA, Ganzer R et al (2009) Primary prostate HIFU without pretreatment hormone therapy: biochemical survival of 468 patients tracked with the @-registry. J Urol 181(4):227CrossRefGoogle Scholar
  13. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H (2001) Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 165(1):119–125PubMedCrossRefGoogle Scholar
  14. Borghede G, Aldenborg F, Wurzinger E, Johansson KA, Hedelin H (1997) Analysis of the local control in lymph-node staged localized prostate cancer treated by external beam radiotherapy, assessed by digital rectal examination, serum prostate-specific antigen and biopsy. Br J Urol 80(2):247–255PubMedCrossRefGoogle Scholar
  15. Bosetti C, Bertuccio P, Chatenoud L, Negri E, La Vecchia C, Levi F (2011) Trends in mortality from urologic cancers in Europe, 1970–2008. Eur Urol 60(1):1–15PubMedCrossRefGoogle Scholar
  16. Bratan F, Niaf E, Chesnais AL, Souchon R, Mège-Lechevalier F, Rouvière O (2011) Detection and localization of prostate cancers using multiparametric magnetic resonance imaging. 97th scientific assembly and annual meeting of the Radiological Society of North America, Chicago, 27 Nov–2 Dec 2011Google Scholar
  17. Challacombe BJ, Murphy DG, Zakri R, Cahill DJ (2009) High-intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-up. BJU Int 104(2):200–204PubMedCrossRefGoogle Scholar
  18. Chapelon JY, Margonari J, Vernier F, Gorry F, Ecochard R, Gelet A (1992) In vivo effects of high-intensity ultrasound on prostatic adenocarcinoma dunning R3327. Cancer Res 52(22):6353–6357PubMedGoogle Scholar
  19. Chaussy C, Thuroff S (2001) Results and side effects of high-intensity focused ultrasound in localized prostate cancer. J Endourol 15(4):437–440; discussion 47–8PubMedCrossRefGoogle Scholar
  20. Chaussy C, Thuroff S (2003) The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 4(3):248–252PubMedCrossRefGoogle Scholar
  21. Chaussy C, Thuroff S, Rebillard X, Gelet A (2005) Technology insight: High-intensity focused ultrasound for urologic cancers. Nat Clin Pract Urol 2(4):191–198PubMedCrossRefGoogle Scholar
  22. Chavrier F, Chapelon JY, Gelet A, Cathignol D (2000) Modeling of high-intensity focused ultrasound-induced lesions in the presence of cavitation bubbles. J Acoust Soc Am 108(1):432–440PubMedCrossRefGoogle Scholar
  23. Cheikh AB, Girouin N, Colombel M, Marechal JM, Gelet A, Bissery A et al (2009) Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol 19(3):770–778PubMedCrossRefGoogle Scholar
  24. Chopra R, Burtnyk M, Haider MA, Bronskill MJ (2005) Method for MRI-guided conformal thermal therapy of prostate with planar transurethral ultrasound heating applicators. Phys Med Biol 50(21):4957–4975PubMedCrossRefGoogle Scholar
  25. Conti SL, Dall’era M, Fradet V, Cowan JE, Simko J, Carroll PR (2009) Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 181(4):1628–1633; discussion 33–4PubMedCrossRefGoogle Scholar
  26. Crouzet S, Rebillard X, Chevallier D, Rischmann P, Pasticier G, Garcia G et al (2010a) Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients. Eur Urol 58(4):559–566PubMedCrossRefGoogle Scholar
  27. Crouzet S, Murat FJ, Rouviere O, Poissonnier L, Martin X, Colombel M et al (2010) Outcomes of HIFU for prostate cancer in 880 consecutive patients. In: AUA annual meeting, San Francisco, 2010; MP58(1006962)Google Scholar
  28. Crouzet S, Poissonnier L, Murat FJ, Pasticier G, Rouviere O, Mege-Lechevallier F et al (2011) Outcomes of HIFU for localised prostate cancer using the ablatherm integrate imaging(R) device. Prog Urol 21(3):191–197PubMedCrossRefGoogle Scholar
  29. Eisenberg ML, Shinohara K (2008) Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure. Urology 72(6):1315–1318PubMedCrossRefGoogle Scholar
  30. Ficarra V, Antoniolli SZ, Novara G, Parisi A, Fracalanza S, Martignoni G et al (2006) Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU Int 98(6):1193–1198PubMedCrossRefGoogle Scholar
  31. Ganzer R, Rogenhofer S, Walter B, Lunz JC, Schostak M, Wieland WF et al (2008) PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. Eur Urol 53(3):547–553PubMedCrossRefGoogle Scholar
  32. Gelet A, Chapelon JY, Margonari J, Theillere Y, Gorry F, Cathignol D et al (1993a) Prostatic tissue destruction by high-intensity focused ultrasound: experimentation on canine prostate. J Endourol 7(3):249–253PubMedCrossRefGoogle Scholar
  33. Gelet A, Chapelon JY, Margonari J, Theillere Y, Gorry F, Souchon R et al (1993b) High-intensity focused ultrasound experimentation on human benign prostatic hypertrophy. Eur Urol 23(Suppl 1):44–47PubMedGoogle Scholar
  34. Gelet A, Chapelon JY, Bouvier R, Souchon R, Pangaud C, Abdelrahim AF et al (1996) Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol 29(2):174–183PubMedGoogle Scholar
  35. Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y (1999) Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results. J Urol 161(1):156–162PubMedCrossRefGoogle Scholar
  36. Gelet A, Chapelon JY, Bouvier R, Rouviere O, Lasne Y, Lyonnet D et al (2000) Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J Endourol 14(6):519–528PubMedCrossRefGoogle Scholar
  37. Girouin N, Mege-Lechevallier F, Tonina Senes A, Bissery A, Rabilloud M, Marechal JM et al (2007) Prostate dynamic contrast-enhanced MRI with simple Visual diagnostic criteria: Is it reasonable? Eur Radiol 17(6):1498–1509PubMedCrossRefGoogle Scholar
  38. Haider MA, Chung P, Sweet J, Toi A, Jhaveri K, Menard C et al (2008) Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 70(2):425–430PubMedCrossRefGoogle Scholar
  39. Heidenreich A, Richter S, Thuer D, Pfister D (2010) Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol 57(3):437–443PubMedCrossRefGoogle Scholar
  40. Hynynen K, Darkazanli A, Unger E, Schenck JF (1993) MRI-guided noninvasive ultrasound surgery. Med Phys 20(1):107–115PubMedCrossRefGoogle Scholar
  41. Hynynen K, Colucci V, Chung A, Jolesz F (1996) Noninvasive arterial occlusion using MRI-guided focused ultrasound. Ultrasound Med Biol 22(8):1071–1077PubMedCrossRefGoogle Scholar
  42. Ishihara Y, Calderon A, Watanabe H, Okamoto K, Suzuki Y, Kuroda K (1995) A precise and fast temperature mapping using water proton chemical shift. Magn Reson Med 34(6):814–823PubMedCrossRefGoogle Scholar
  43. Kennedy JE, Ter Haar GR, Cranston D (2003) High intensity focused ultrasound: surgery of the future? Br J Radiol 76(909):590–599PubMedCrossRefGoogle Scholar
  44. Kirkham AP, Emberton M, Hoh IM, Illing RO, Freeman AA, Allen C (2008) MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology 246(3):833–844PubMedCrossRefGoogle Scholar
  45. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28(1):126–131PubMedCrossRefGoogle Scholar
  46. Koch MO, Gardner T, Cheng L, Fedewa RJ, Seip R, Sanghvi NT (2007) Phase I/II trial of high intensity focused ultrasound for the treatment of previously untreated localized prostate cancer. J Urol 178(6):2366–2370; discussion 70–1PubMedCrossRefGoogle Scholar
  47. Kuroda K, Chung AH, Hynynen K, Jolesz FA (1998) Calibration of water proton chemical shift with temperature for noninvasive temperature imaging during focused ultrasound surgery. J Magn Reson Imaging 8(1):175–181PubMedCrossRefGoogle Scholar
  48. Larrat B, Pernot M, Aubry JF, Dervishi E, Sinkus R, Seilhean D et al (2010) MR-guided transcranial brain HIFU in small animal models. Phys Med Biol 55(2):365–388PubMedCrossRefGoogle Scholar
  49. Lawrentschuk N, Finelli A, Van der Kwast TH, Ryan P, Bolton DM, Fleshner NE et al (2011) Salvage radical prostatectomy following primary high intensity focused ultrasound for treatment of prostate cancer. J Urol 185(3):862–868PubMedCrossRefGoogle Scholar
  50. Leach MO (2009) Breast cancer screening in women at high risk using MRI. NMR Biomed 22(1):17–27PubMedCrossRefGoogle Scholar
  51. Lee HM, Hong JH, Choi HY (2006) High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 9(4):439–443PubMedCrossRefGoogle Scholar
  52. Lemaitre L, Puech P, Poncelet E, Bouye S, Leroy X, Biserte J et al (2009) Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. Eur Radiol 19(2):470–480PubMedCrossRefGoogle Scholar
  53. Li LY, Lin Z, Yang M, Gao X, Xia TL, Ding T (2010) Comparison of penile size and erectile function after high-intensity focused ultrasound and targeted cryoablation for localized prostate cancer: a prospective pilot study. J Sex Med 7(9):3135–3142PubMedCrossRefGoogle Scholar
  54. Lynn JG, Putnam TJ (1944) Histology of cerebral lesions produced by focused ultrasound. Am J Pathol 20(3):637–649PubMedGoogle Scholar
  55. Lynn JG, Zwemer RL, Chick AJ (1942) The biological application of focused ultrasonic waves. Science 96(2483):119–120PubMedCrossRefGoogle Scholar
  56. Madersbacher S, Kratzik C, Szabo N, Susani M, Vingers L, Marberger M (1993) Tissue ablation in benign prostatic hyperplasia with high-intensity focused ultrasound. Eur Urol 23(Suppl 1):39–43PubMedGoogle Scholar
  57. Maestroni U, Ziveri M, Azzolini N, Dinale F, Ziglioli F, Campaniello G et al (2008) High intensity focused ultrasound (HIFU): a useful alternative choice in prostate cancer treatment. Preliminary results. Acta Biomed 79(3):211–216PubMedGoogle Scholar
  58. McDannold N (2005) Quantitative MRI-based temperature mapping based on the proton resonant frequency shift: review of validation studies. Int J Hyperthermia 21(6):533–546PubMedCrossRefGoogle Scholar
  59. McDannold NJ, King RL, Jolesz FA, Hynynen KH (2000) Usefulness of MR imaging-derived thermometry and dosimetry in determining the threshold for tissue damage induced by thermal surgery in rabbits. Radiology 216(2):517–523PubMedGoogle Scholar
  60. Mearini L, D’Urso L, Collura D, Zucchi A, Costantini E, Formiconi A et al (2009) Visually directed transrectal high intensity focused ultrasound for the treatment of prostate cancer: a preliminary report on the Italian experience. J Urol 181(1):105–111; discussion 11–2PubMedCrossRefGoogle Scholar
  61. Melodelima D, Salomir R, Mougenot C, Prat F, Theillere Y, Moonen C et al (2004) Intraluminal ultrasound applicator compatible with magnetic resonance imaging “real-time” temperature mapping for the treatment of oesophageal tumours: an ex vivo study. Med Phys 31(2):236–244PubMedCrossRefGoogle Scholar
  62. Misrai V, Roupret M, Chartier-Kastler E, Comperat E, Renard-Penna R, Haertig A et al (2008) Oncologic control provided by HIFU therapy as single treatment in men with clinically localized prostate cancer. World J Urol 26(5):481–485PubMedCrossRefGoogle Scholar
  63. Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ (2007) Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 110(4):906–910PubMedCrossRefGoogle Scholar
  64. Murat FJ, Poissonnier L, Rabilloud M, Belot A, Bouvier R, Rouviere O et al (2009) Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol 55(3):640–647PubMedCrossRefGoogle Scholar
  65. Muto S, Yoshii T, Saito K, Kamiyama Y, Ide H, Horie S (2008) Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol 38(3):192–199PubMedCrossRefGoogle Scholar
  66. Netsch C, Pfeiffer D, Gross AJ (2010) Development of bladder outlet obstruction after a single treatment of prostate cancer with high-intensity focused ultrasound: experience with 226 patients. J Endourol 24(9):1399–1403PubMedCrossRefGoogle Scholar
  67. Niaf E, Lartizien C, Rouvière O (2011) Computer-aided diagnosis for prostate cancer detection in the peripheral zone via multisequence MRI. In: SPIE conference Munich, GermanyGoogle Scholar
  68. Noguchi M, Stamey TA, McNeal JE, Nolley R (2003) Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 170(2 Pt 1):459–463PubMedCrossRefGoogle Scholar
  69. Okada A, Morita Y, Fukunishi H, Takeichi K, Murakami T (2009) Non-invasive magnetic resonance-guided focused ultrasound treatment of uterine fibroids in a large Japanese population: impact of the learning curve on patient outcome. Ultrasound Obstet Gynecol 34(5):579–583PubMedCrossRefGoogle Scholar
  70. Paparel P, Curiel L, Chesnais S, Ecochard R, Chapelon JY, Gelet A (2005) Synergistic inhibitory effect of high-intensity focused ultrasound combined with chemotherapy on dunning adenocarcinoma. BJU Int 95(6):881–885PubMedCrossRefGoogle Scholar
  71. Paparel P, Chapelon JY, Bissery A, Chesnais S, Curiel L, Gelet A (2008) Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of dunning tumors: results of a preliminary study. Prostate Cancer Prostatic Dis 11(2):181–186PubMedCrossRefGoogle Scholar
  72. Pasticier G, Chapet O, Badet L, Ardiet JM, Poissonnier L, Murat FJ et al (2008) Salvage radiotherapy after high-intensity focused ultrasound for localized prostate cancer: early clinical results. Urology 72(6):1305–1309PubMedCrossRefGoogle Scholar
  73. Pasticier G, Riviere J, Wallerand H, Robert G, Bernhard JC, Ferriere JM, et al (2010) Salvage radiotherapy (SRT) for local recurrence of prostate adenocarcinoma after primary treatment with high intensity focused ultrasound (HIFU): first series of 100 patients. 2010 ASCO annual meeting Chicago, USAGoogle Scholar
  74. Peters RD, Hinks RS, Henkelman RM (1998) Ex vivo tissue-type independence in proton-resonance frequency shift MR thermometry. Magn Reson Med 40(3):454–459PubMedCrossRefGoogle Scholar
  75. Poissonnier L, Chapelon JY, Rouviere O, Curiel L, Bouvier R, Martin X et al (2007) Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 51(2):381–387PubMedCrossRefGoogle Scholar
  76. Puech P, Betrouni N, Makni N, Dewalle A, Villers A, Lemaitre L (2009) Computer-assisted diagnosis of prostate cancer using DCE-MRI data: implementation and preliminary results. Int J Comput Assist Radiol Surg 4(1):1–10PubMedCrossRefGoogle Scholar
  77. Quesson B, de Zwart JA, Moonen CT (2000) Magnetic resonance temperature imaging for guidance of thermotherapy. J Magn Reson Imaging 12(4):525–533PubMedCrossRefGoogle Scholar
  78. Quesson B, Laurent C, Maclair G, de Senneville BD, Mougenot C, Ries M et al (2011) Real-time volumetric MRI thermometry of focused ultrasound ablation in vivo: a feasibility study in pig liver and kidney. NMR Biomed 24(2):145–153PubMedCrossRefGoogle Scholar
  79. Rebillard X, Davin JL, Soulie M (2003) Treatment by HIFU of prostate cancer: survey of literature and treatment indications. Prog Urol 13(6):1428–1456PubMedGoogle Scholar
  80. Rieke V, Butts Pauly K (2008) MR thermometry. J Magn Reson Imaging 27(2):376–390PubMedCrossRefGoogle Scholar
  81. Ripert T, Bayoud Y, Messaoudi R, Menard J, Azemar MD, Duval F, et al (2011) Salvage radiotherapy after high-intensity focused ultrasound treatment for localized prostate cancer: feasibility, tolerance and efficacy. Canadian Urological Association journal = Journal de l’Association des urologues du Canada. 1 May, pp 1–5Google Scholar
  82. Rouviere O, Lyonnet D, Raudrant A, Colin-Pangaud C, Chapelon JY, Bouvier R et al (2001) MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 40(3):265–274PubMedCrossRefGoogle Scholar
  83. Rouviere O, Valette O, Grivolat S, Colin-Pangaud C, Bouvier R, Chapelon JY et al (2004) Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor–correlation with biopsy findings. Urology 63(5):922–927PubMedCrossRefGoogle Scholar
  84. Rouviere O, Mege-Lechevallier F, Chapelon JY, Gelet A, Bouvier R, Boutitie F et al (2006) Evaluation of color Doppler in guiding prostate biopsy after HIFU ablation. Eur Urol 50(3):490–497PubMedCrossRefGoogle Scholar
  85. Rouviere O, Souchon R, Salomir R, Gelet A, Chapelon JY, Lyonnet D (2007) Transrectal high-intensity focused ultrasound ablation of prostate cancer: effective treatment requiring accurate imaging. Eur J Radiol 63(3):317–327PubMedCrossRefGoogle Scholar
  86. Rouviere O, Girouin N, Glas L, Ben Cheikh A, Gelet A, Mege-Lechevallier F et al (2010) Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol 20(1):48–55PubMedCrossRefGoogle Scholar
  87. Rouvière O, Glas L, Girouin N, Mège-Lechevallier F, Gelet A, Dantony E et al (2011) Prostate cancer ablation with transrectal high-intensity focused ultrasound: Assessment of tissue destruction with contrast-enhanced. US Radiol 259:583–591Google Scholar
  88. Salomir R, Vimeux FC, de Zwart JA, Grenier N, Moonen CT (2000) Hyperthermia by MR-guided focused ultrasound: accurate temperature control based on fast MRI and a physical model of local energy deposition and heat conduction. Magn Reson Med 43(3):342–347PubMedCrossRefGoogle Scholar
  89. Salomir R, Delemazure AS, Palussiere J, Rouviere O, Cotton F, Chapelon JY (2006) Image-based control of the magnetic resonance imaging-guided focused ultrasound thermotherapy. Top Magn Reson Imaging 17(3):139–151PubMedCrossRefGoogle Scholar
  90. Shoji S, Nakano M, Nagata Y, Usui Y, Terachi T, Uchida T (2010) Quality of life following high-intensity focused ultrasound for the treatment of localized prostate cancer: a prospective study. Int J Urol 17(8):715–719PubMedCrossRefGoogle Scholar
  91. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM (1999) Biological determinants of cancer progression in men with prostate cancer. JAMA 281(15):1395–1400PubMedCrossRefGoogle Scholar
  92. Sumitomo M, Asakuma J, Sato A, Ito K, Nagakura K, Asano T (2010) Transurethral resection of the prostate immediately after high-intensity focused ultrasound treatment for prostate cancer. Int J Urol 17(11):924–930PubMedCrossRefGoogle Scholar
  93. Sylvester JE, Grimm PD, Wong J, Galbreath RW, Merrick G, Blasko JC (2011) Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys 81:376–381PubMedCrossRefGoogle Scholar
  94. Thuroff S, Chaussy C (2000) High-intensity focused ultrasound: complications and adverse events. Mol Urol 4(3):183–187; discussion 9PubMedGoogle Scholar
  95. Thuroff S, Chaussy C, Vallancien G, Wieland W, Kiel HJ, Le Duc A et al (2003) High-intensity focused ­ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 17(8):673–677PubMedCrossRefGoogle Scholar
  96. Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL et al (2010) Prostate cancer: value of multiparametric MR imaging at 3 T for detection–histopathologic correlation. Radiology 255(1):89–99PubMedCrossRefGoogle Scholar
  97. Uchida T, Ohkusa H, Nagata Y, Hyodo T, Satoh T, Irie A (2006a) Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 97(1):56–61PubMedCrossRefGoogle Scholar
  98. Uchida T, Ohkusa H, Yamashita H, Shoji S, Nagata Y, Hyodo T et al (2006b) Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 13(3):228–233PubMedCrossRefGoogle Scholar
  99. Uchida T, Illing RO, Cathcart PJ, Emberton M (2006c) To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 98(3):537–539PubMedCrossRefGoogle Scholar
  100. Uchida T, Nakano M, Shoji S, Omaat T, Harano H, Nagata Y et al (2009) Ten year biochemical disease free survival after high intensity focused ultrasound (HIFU) for localised prostate cancer: comparison with three different generation devices. J Urol 181(4):228CrossRefGoogle Scholar
  101. Uchida T, Shoji S, Nakano M, Hongo S, Nitta M, Usui Y et al (2010) High-intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after external beam radiation, brachytherapy or proton therapy. BJU Int 107(3):378–382PubMedCrossRefGoogle Scholar
  102. Vallancien G, Prapotnich D, Cathelineau X, Baumert H, Rozet F (2004) Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol 171(6 Pt 1):2265–2267PubMedCrossRefGoogle Scholar
  103. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L (2006) Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 176(6 Pt 1):2432–2437PubMedCrossRefGoogle Scholar
  104. Wise AM, Stamey TA, McNeal JE, Clayton JL (2002) Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 60(2):264–269PubMedCrossRefGoogle Scholar
  105. Zacharakis E, Ahmed HU, Ishaq A, Scott R, Illing R, Freeman A et al (2008) The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int 102(7):786–792PubMedCrossRefGoogle Scholar
  106. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC et al (2001) High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166(3):876–881PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Department of Urology and TransplantationEdouard Herriot HospitalCedex 03, LyonFrance
  2. 2.Therapeutic Ultrasound Research LaboratoryUniversité de Lyon, Inserm, U1032LyonFrance
  3. 3.Department of RadiologyEdouard Herriot HospitalLyonFrance

Personalised recommendations